Temporal trends in the prevalence, incidence, and mortality of cardiac amyloidosis in Korea over 12 years
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
OBJECTIVES: This study investigated the prevalence, incidence, and prognosis of cardiac amyloidosis (CA) in Korea.METHODS: This retrospective nationwide population-based study used the Health Insurance Review and Assessment Service databases between 2008 and 2020. All patients diagnosed with amyloidosis were included, and those with a diagnosis of heart failure or cardiomyopathy were classified as having CA. Both the special code for amyloidosis (V121), which enables coverage of medical expenses, and the corresponding International Classification of Diseases, 10th revision codes for amyloidosis (E850- E854, E858, E859) were used to improve the reliability of amyloidosis diagnosis.RESULTS: Among 2,239 patients with amyloidosis, 758 met the criteria for CA (mean age, 64.4±11.9 years; 59.1% male). The mean age of patients with CA increased from 59.5±14.7 years in 2009 to 68.1±13.9 years in 2020. The incidence and prevalence increased from 0.09 (95% confidence interval [CI], 0.06 to 0.12) to 0.22 (95% CI, 0.18 to 0.27) per 100,000 person-years and 0.20 (95% CI, 0.16 to 0.25) to 1.30 (95% CI, 0.12 to 0.42) per 100,000 persons, respectively (all p<0.001). Patients with light-chain CA showed similar trends. In-hospital mortality decreased from 17.3% (95% CI, 9.23 to 29.6) to 6.10% (95% CI, 4.21 to 8.48) between 2009 and 2020. While age-specific in-hospital mortality was significantly higher in patients aged ≥70 years (p=0.004), no significant age-specific difference in in-hospital mortality was observed in patients with CA aged <70 years (p=0.981).CONCLUSIONS: The prevalence and incidence of CA have increased in Korea, predominantly affecting older individuals, particularly males. Notably, in-hospital mortality decreased significantly.
Abstract
OBJECTIVES: This study investigated the prevalence, incidence, and prognosis of cardiac amyloidosis (CA) in Korea.METHODS: This retrospective nationwide population-based study used the Health Insurance Review and Assessment Service databases between 2008 and 2020. All patients diagnosed with amyloidosis were included, and those with a diagnosis of heart failure or cardiomyopathy were classified as having CA. Both the special code for amyloidosis (V121), which enables coverage of medical expenses, and the corresponding International Classification of Diseases, 10th revision codes for amyloidosis (E850- E854, E858, E859) were used to improve the reliability of amyloidosis diagnosis.RESULTS: Among 2,239 patients with amyloidosis, 758 met the criteria for CA (mean age, 64.4±11.9 years; 59.1% male). The mean age of patients with CA increased from 59.5±14.7 years in 2009 to 68.1±13.9 years in 2020. The incidence and prevalence increased from 0.09 (95% confidence interval [CI], 0.06 to 0.12) to 0.22 (95% CI, 0.18 to 0.27) per 100,000 person-years and 0.20 (95% CI, 0.16 to 0.25) to 1.30 (95% CI, 0.12 to 0.42) per 100,000 persons, respectively (all p<0.001). Patients with light-chain CA showed similar trends. In-hospital mortality decreased from 17.3% (95% CI, 9.23 to 29.6) to 6.10% (95% CI, 4.21 to 8.48) between 2009 and 2020. While age-specific in-hospital mortality was significantly higher in patients aged ≥70 years (p=0.004), no significant age-specific difference in in-hospital mortality was observed in patients with CA aged <70 years (p=0.981).CONCLUSIONS: The prevalence and incidence of CA have increased in Korea, predominantly affecting older individuals, particularly males. Notably, in-hospital mortality decreased significantly.
참고문헌 (25)
- Quarta CC, "Cardiac amyloidosis", Circulation, 126, pp.e178~e182 (2012)[DOI]
- Maleszewski JJ, "Cardiac amyloidosis : pathology, nomenclature, and typing", Cardiovasc Pathol, 24, pp.343~350 (2015)[DOI]
- Lee SP, "Contemporary imaging diagnosis of cardiac amyloidosis", J Cardiovasc Imaging, 27, pp.1~10 (2019)[DOI]
- Macedo AV, "Advances in the treatment of cardiac amyloidosis", Curr Treat Options Oncol, 21, pp.36~ (2020)[DOI]
- Phipps C, "Daratumumab and its potential in the treatment of multiple myeloma : overview of the preclinical and clinical development", Ther Adv Hematol, 6, pp.120~127 (2015)[DOI]
- Kastritis E, "Recent advances in the management of AL Amyloidosis", Br J Haematol, 172, pp.170~186 (2016)[DOI]
- Maurer MS, "Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy", N Engl J Med, 379, pp.1007~1016 (2018)[DOI]
- Kim D, "Untangling amyloidosis : recent advances in cardiac amyloidosis", Int J Heart Fail, 2, pp.231~239 (2020)[DOI]
- Rozenbaum MH, "Impact of delayed diagnosis and misdiagnosis for patients with transthyretin amyloid cardiomyopathy(ATTR-CM) : a targeted literature review", Cardiol Ther, 10, pp.141~159 (2021)[DOI]
- Maurer MS, "Addressing common questions encountered in the diagnosis and management of cardiac amyloidosis", Circulation, 135, pp.1357~1377 (2017)[DOI]
- Lee MH, "Incidence, diagnosis and prognosis of cardiac amyloidosis", Korean Circ J, 43, pp.752~760 (2013)[DOI]
- Gilstrap LG, "Epidemiology of cardiac amyloidosis-associated heart failure hospitalizations among fee-for-service medicare beneficiaries in the United States", Circ Heart Fail, 12, pp.e005407~ (2019)[DOI]
- Choi YJ, "Emergency department utilization in patients with hypertrophic cardiomyopathy : a nationwide population-based study", Sci Rep, 12, pp.3534~ (2022)[DOI]
- Choi YJ, "Augmented risk of ischemic stroke in hypertrophic cardiomyopathy patients without documented atrial fibrillation", Sci Rep, 12, pp.15785~ (2022)[DOI]
- Krishnappa D, "Atrial fibrillation in the elderly : the role of sub-clinical isolated cardiac amyloidosis", Sci Rep, 9, pp.16584~ (2019)[DOI]
- González-López E, "Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction", Eur Heart J, 36, pp.2585~2594 (2015)[DOI]
- Nitsche C, "Prevalence and outcomes of concomitant aortic stenosis and cardiac amyloidosis", J Am Coll Cardiol, 77, pp.128~139 (2021)[DOI]
- Seo SR, "Prevalence of amyloidosis in Korea", Orphanet J Rare Dis, 12, pp.152~ (2017)[DOI]
- Yoon SE, "A comprehensive overview of AL amyloidosis disease characteristics accumulated over two decades at a single referral center in Korea", Int J Hematol, 117, pp.706~717 (2023)[DOI]
- Staron A, "Marked progress in AL amyloidosis survival : a 40-year longitudinal natural history study", Blood Cancer J, 11, pp.139~ (2021)[DOI]
- Dispenzieri A, "Real-world treatment patterns, costs, and outcomes in patients with AL amyloidosis : analysis of the Optum EHR and commercial claims databases", Amyloid, 30, pp.161~168 (2023)[DOI]
- Westin O, "Two decades of cardiac amyloidosis : a Danish nationwide study", JACC CardioOncol, 3, pp.522~533 (2021)[DOI]
- Kumar N, "Global epidemiology of amyloid light-chain amyloidosis", Orphanet J Rare Dis, 17, pp.278~ (2022)[DOI]
- Jang SC, "Clinical manifestation, economic burden, and mortality in patients with transthyretin cardiac amyloidosis", Orphanet J Rare Dis, 17, pp.262~ (2022)[DOI]
- Griffin JM, "ATTR amyloidosis : current and emerging management strategies : JACC : cardiooncology state-of-the-art review", JACC CardioOncol, 3, pp.488~505 (2021)[DOI]